Kiadis Pharma has a number of novel products in clinical development and a portfolio of preclinical programs all derived from the company's product and technology platforms.

The current status of our products in clinical development:

• ATIR™ : Phase I/II study for hematopoietic stem cell transplantations (HSCT) is closed for enrollment.

• Reviroc™: Phase II study completed

• Rhitol™:  Phase I/II study is completed